Tremelimumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.

**Synonyms:** - Anti-CTLA4 Human Monoclonal Antibody CP-675,206 - CP 675 - CP 675206 - CP-675 - CP-675,206 - CP-675206 - CP675 - CP675206 - Imjudo - Immunoglobulin G2, Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Dimer - TREMELIMUMAB - Ticilimumab - Tremelimumab-actl - ticilimumab